Search clinical trials for: Letetresgene autoleucel

Total 58 results

GlaxoSmithKline
Merck Sharp & Dohme LLC

Terminated

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Neoplasms

United States
GlaxoSmithKline

Completed

Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

Neoplasms

United States
GlaxoSmithKline

Active, not recruiting

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Neoplasms

United States, Netherlands, Canada, United Kingdom
GlaxoSmithKline

Completed

Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Neoplasms

United States
Adaptimmune

Active, not recruiting

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

Neoplasms

United States, Canada, Spain, United Kingdom, Netherlands, France, Italy
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

Relmacabtagene Autoleucel in Patients With LBCL

Large B-cell Lymphoma

China
Adaptimmune

Recruiting

SPEARHEAD-3 Pediatric Study

Osteosarcoma | Neuroblastoma | Synovial Sarcoma | Malignant Peripheral Nerve Sheath Tumor (MPNST)

United States
Peking University People's Hospital

Not yet recruiting

A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.

Relapsed/Refractory Multiple Myeloma

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Not yet recruiting

Relmacabtagene Autoleucel in Hematologic Malignancies

Lymphoma, B-Cell | Follicular Lymphoma | Large B-cell Lymphoma

China
Shanghai Ming Ju Biotechnology Co., Ltd.
The First Affiliated Hospital with Nanjing Medical University

Not yet recruiting

Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL

Leukemia, Lymphocytic, Chronic, B-Cell

China
First Affiliated Hospital of Zhejiang University
Cellular Biomedicine Group Ltd.

Active, not recruiting

A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma

Non-Hodgkin's B-cell Lymphoma

China
Tianjin Medical University Cancer Institute and...
Cellular Biomedicine Group Ltd.

Active, not recruiting

A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma

Non-Hodgkin's B-cell Lymphoma

China
Kite, A Gilead Company

Available

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma

United States
Changhai Hospital

Not yet recruiting

A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma

Relapsed or Refractory B-cell Lymphoma
Ruijin Hospital

Recruiting

Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma

Relapsed or Refractory B-cell Lymphoma

China
Cellular Biomedicine Group Ltd.

Recruiting

A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma (ELEVATION)

Relapsed/Refractory Large B-Cell Lymphoma

China
Kite, A Gilead Company
Arcellx, Inc.

Recruiting

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) (iMMagine-1)

Multiple Myeloma

United States
Shanghai Tongji Hospital, Tongji University School...
Cellular Biomedicine Group Ltd.

Active, not recruiting

A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects

Non-Hodgkin's B-cell Lymphoma

China
Adaptimmune

Recruiting

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Myxoid Liposarcoma | Synovial Sarcoma

United States, United Kingdom, Canada, France, Spain
Novartis Pharmaceuticals

Recruiting

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL

Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma | Large B-cell Lymphoma

Japan, Australia, Germany, Spain, Italy, United States, France, Austria
Ruijin Hospital

Not yet recruiting

CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors

B-NHL, Extranodal, TP53 Alterations, Bulky Mass
Nanjing Legend Biotech Co.
Janssen Research & Development, LLC

Recruiting

A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma (CARTIFAN-1)

Multiple Myeloma

China
Kite, A Gilead Company
Arcellx, Inc.

Recruiting

Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma

Relapsed and Refractory Multiple Myeloma

United States
Autolus Limited

Recruiting

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

United Kingdom
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Enrolling by invitation

A Long-term Follow-up Study in Participants Who Received CTX001

Hematologic Diseases | Genetic Diseases, Inborn | Sickle Cell Disease | Hemoglobinopathies | Sickle Cell Anemia | Thalassemia | Beta-Thalassemia

United States, Canada, Italy, United Kingdom, Germany
Autolus Limited

Recruiting

A Study of CD19 Targeted CAR T Cell Therapy in Patients With Severe, Refractory Systemic Lupus Erythematosus (SLE) (CARLYSE)

Systemic Lupus Erythematosus

United Kingdom
Autolus Limited

Active, not recruiting

A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

United States, United Kingdom, Spain
Kite, A Gilead Company

Enrolling by invitation

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Solid and Hematological Malignancies

United States, Netherlands, Japan, Australia, France, Israel, Germany, Canada, United Kingdom
H. Lee Moffitt Cancer Center and Research Institute
Kite, A Gilead Company

Recruiting

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Acute Lymphoblastic Leukemia | B-Cell Lymphoblastic Leukemia

United States
Kite, A Gilead Company

Completed

A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) (ZUMA-3)

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

United States, France, Germany, Netherlands, Canada
bluebird bio

Active, not recruiting

Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product

Cerebral Adrenoleukodystrophy (CALD) | Adrenoleukodystrophy (ALD) | X-Linked Adrenoleukodystrophy (X-ALD)

United States, Argentina, Australia, Brazil, France, Germany, Netherlands, United Kingdom, Italy
Kite, A Gilead Company

Recruiting

Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25)

Relapsed/Refractory Waldenstrom Macroglobulinemia | Relapsed/Refractory Richter Transformation | Relapsed/Refractory Burkitt Lymphoma | Relapsed/Refractory Hairy Cell Leukemia

United States, Spain, Germany, Italy, France, Netherlands, Switzerland, Austria
Kite, A Gilead Company

Terminated

Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ZUMA-8)

Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma

United States, Italy
Kite, A Gilead Company

Recruiting

Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Spain, United States, Canada, Belgium, Poland, Czechia, Italy, France, Germany, Netherlands, Sweden
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia

Hematologic Diseases | Genetic Diseases, Inborn | Hemoglobinopathies | Thalassemia | Beta-Thalassemia

United States, United Kingdom, Germany, Canada, Italy
Kite, A Gilead Company

Completed

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) (ZUMA-2)

Relapsed/Refractory Mantle Cell Lymphoma

United States, Netherlands, Germany, France
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Recruiting

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)

Sickle Cell Disease | Hemoglobinopathies | Hematological Diseases | Hydroxyurea Failure | Hydroxyurea Intolerance

United States, Italy, United Kingdom, Germany
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease

Sickle Cell Disease | Hemoglobinopathies | Hematological Diseases

United States, Belgium, Canada, France, Germany, Italy, United Kingdom
Vertex Pharmaceuticals Incorporated

Not yet recruiting

Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/βC Genotype

Sickle Cell Disease
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Recruiting

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

Hematologic Diseases | Genetic Diseases, Inborn | Sickle Cell Disease | Hemoglobinopathies | Sickle Cell Anemia | Thalassemia | Beta-Thalassemia

United States, Italy, Germany
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Recruiting

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

Hematologic Diseases | Genetic Diseases, Inborn | Hemoglobinopathies | Thalassemia | Beta-Thalassemia

United States, Germany, Italy, United Kingdom, Canada
bluebird bio

Completed

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia

Beta-Thalassemia

United States, Germany, United Kingdom, France, Greece, Italy
bluebird bio

Completed

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype

Beta-Thalassemia

France, United Kingdom, United States, Thailand, Italy, Germany
bluebird bio

Completed

A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)

Cerebral Adrenoleukodystrophy (CALD)

United States, France, Germany, Italy, Netherlands, United Kingdom
M.D. Anderson Cancer Center
Kite, A Gilead Company; Acerta Pharma, LLC

Recruiting

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

Lymphoma | Mantle Cell Lymphoma

United States
Lantu Biopharma

Not yet recruiting

An Open-label Study of a Gene Therapy Product in Beta-Thalassemia

Beta-Thalassemia
bluebird bio

Completed

A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)

Cerebral Adrenoleukodystrophy (CALD)

United States, Germany, Argentina, Australia, France, United Kingdom
Peking University Cancer Hospital & Institute
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma

B-cell Lymphoma

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Not yet recruiting

Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL

Lymphoma, Large B-Cell, Diffuse | High-grade B-cell Lymphoma | Follicular Lymphoma Grade 3B | Mediastinal B-Cell Diffuse Large Cell Lymphoma

China
Kite, A Gilead Company

Approved for marketing

Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies (ZUMA-18)

Relapse/Refractory Mantle Cell Lymphoma

United States

Search clinical trials for: Letetresgene autoleucel

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations